Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective
Abstract: Concerns remain regarding the rare cardiovascular adverse events, myocarditis and pericarditis (myo/pericarditis), particularly in younger individuals following mRNA COVID-19 vaccination. Our study aimed to comprehensively assess potential safety signals related to these cardiac events following the primary and booster doses, with a specific focus on younger populations, including children as young as 6 months of age. Using the Vaccine Adverse Events Reporting System (VAERS), the United States national passive surveillance system, we conducted a retrospective pharmacovigilance study analyzing spontaneous reports of myo/pericarditis. We employed both frequentist and Bayesian methods and conducted subgroup analyses by age, sex, and vaccine dose. We observed a higher reporting rate of myo/pericarditis following the primary vaccine series, particularly in males and mainly after the second dose. However, booster doses demonstrated a lower number of reported cases, with no significant signals detected after the fourth or fifth doses. In children and young adults, we observed notable age and sex differences in the reporting of myo/pericarditis cases. Males in the 12–17 and 18–24-year-old age groups had the highest number of cases, with significant signals for both males and females after the second dose. We also identified an increased reporting for a spectrum of cardiovascular symptoms such as chest pain and dyspnea, which increased with age, and were reported more frequently than myo/pericarditis. The present study identified signals of myo/pericarditis and related cardiovascular symptoms after mRNA COVID-19 vaccination, especially among children and adolescents. These findings underline the importance for continued vaccine surveillance and the need for further studies to confirm these results and to determine their clinical implications in public health decision-making, especially for younger populations.
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Artículo biblioteca |
Language: | eng |
Published: |
MDPI
2023
|
Subjects: | MIOCARDITIS, PERICARDITIS, FARMACOVIGILANCIA, COVID-19, VACUNACION, |
Online Access: | https://repositorio.uca.edu.ar/handle/123456789/17345 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:ucacris:123456789-17345 |
---|---|
record_format |
koha |
spelling |
oai:ucacris:123456789-173452023-11-23T18:04:11Z Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective Alami, Abdallah Villeneuve, Paul J. Farrell, Patrick J. Mattison, Donald Farhat, Nawal Haddad, Nisrine Wilson, Kumanan Gravel, Christopher A. Crispo, James A. G. Pérez Lloret, Santiago Krewski, Daniel MIOCARDITIS PERICARDITIS FARMACOVIGILANCIA COVID-19 VACUNACION Abstract: Concerns remain regarding the rare cardiovascular adverse events, myocarditis and pericarditis (myo/pericarditis), particularly in younger individuals following mRNA COVID-19 vaccination. Our study aimed to comprehensively assess potential safety signals related to these cardiac events following the primary and booster doses, with a specific focus on younger populations, including children as young as 6 months of age. Using the Vaccine Adverse Events Reporting System (VAERS), the United States national passive surveillance system, we conducted a retrospective pharmacovigilance study analyzing spontaneous reports of myo/pericarditis. We employed both frequentist and Bayesian methods and conducted subgroup analyses by age, sex, and vaccine dose. We observed a higher reporting rate of myo/pericarditis following the primary vaccine series, particularly in males and mainly after the second dose. However, booster doses demonstrated a lower number of reported cases, with no significant signals detected after the fourth or fifth doses. In children and young adults, we observed notable age and sex differences in the reporting of myo/pericarditis cases. Males in the 12–17 and 18–24-year-old age groups had the highest number of cases, with significant signals for both males and females after the second dose. We also identified an increased reporting for a spectrum of cardiovascular symptoms such as chest pain and dyspnea, which increased with age, and were reported more frequently than myo/pericarditis. The present study identified signals of myo/pericarditis and related cardiovascular symptoms after mRNA COVID-19 vaccination, especially among children and adolescents. These findings underline the importance for continued vaccine surveillance and the need for further studies to confirm these results and to determine their clinical implications in public health decision-making, especially for younger populations. 2023-10-24T11:45:25Z 2023-10-24T11:45:25Z 2023 Artículo Alami, A. et al. Myocarditis and pericarditis post-mrna covid-19 vaccination: insights from a pharmacovigilance perspective [en línea]. Journal of Clinical Medicine. 2023, 12 (15), 4971. doi: 10.3390/jcm12154971. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/17345 2077-0383 https://repositorio.uca.edu.ar/handle/123456789/17345 10.3390/jcm12154971 37568373 eng Acceso abierto http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf MDPI Journal of Clinical Medicine. Vol.12, No.15, 4971, 2023 |
institution |
UCA |
collection |
DSpace |
country |
Argentina |
countrycode |
AR |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-uca |
tag |
biblioteca |
region |
America del Sur |
libraryname |
Sistema de bibliotecas de la UCA |
language |
eng |
topic |
MIOCARDITIS PERICARDITIS FARMACOVIGILANCIA COVID-19 VACUNACION MIOCARDITIS PERICARDITIS FARMACOVIGILANCIA COVID-19 VACUNACION |
spellingShingle |
MIOCARDITIS PERICARDITIS FARMACOVIGILANCIA COVID-19 VACUNACION MIOCARDITIS PERICARDITIS FARMACOVIGILANCIA COVID-19 VACUNACION Alami, Abdallah Villeneuve, Paul J. Farrell, Patrick J. Mattison, Donald Farhat, Nawal Haddad, Nisrine Wilson, Kumanan Gravel, Christopher A. Crispo, James A. G. Pérez Lloret, Santiago Krewski, Daniel Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective |
description |
Abstract: Concerns remain regarding the rare cardiovascular adverse events, myocarditis and pericarditis (myo/pericarditis), particularly in younger individuals following mRNA COVID-19 vaccination. Our study aimed to comprehensively assess potential safety signals related to these cardiac
events following the primary and booster doses, with a specific focus on younger populations,
including children as young as 6 months of age. Using the Vaccine Adverse Events Reporting
System (VAERS), the United States national passive surveillance system, we conducted a retrospective pharmacovigilance study analyzing spontaneous reports of myo/pericarditis. We employed
both frequentist and Bayesian methods and conducted subgroup analyses by age, sex, and vaccine
dose. We observed a higher reporting rate of myo/pericarditis following the primary vaccine series,
particularly in males and mainly after the second dose. However, booster doses demonstrated a
lower number of reported cases, with no significant signals detected after the fourth or fifth doses.
In children and young adults, we observed notable age and sex differences in the reporting of
myo/pericarditis cases. Males in the 12–17 and 18–24-year-old age groups had the highest number of
cases, with significant signals for both males and females after the second dose. We also identified
an increased reporting for a spectrum of cardiovascular symptoms such as chest pain and dyspnea,
which increased with age, and were reported more frequently than myo/pericarditis. The present
study identified signals of myo/pericarditis and related cardiovascular symptoms after mRNA
COVID-19 vaccination, especially among children and adolescents. These findings underline the
importance for continued vaccine surveillance and the need for further studies to confirm these
results and to determine their clinical implications in public health decision-making, especially for
younger populations. |
format |
Artículo |
topic_facet |
MIOCARDITIS PERICARDITIS FARMACOVIGILANCIA COVID-19 VACUNACION |
author |
Alami, Abdallah Villeneuve, Paul J. Farrell, Patrick J. Mattison, Donald Farhat, Nawal Haddad, Nisrine Wilson, Kumanan Gravel, Christopher A. Crispo, James A. G. Pérez Lloret, Santiago Krewski, Daniel |
author_facet |
Alami, Abdallah Villeneuve, Paul J. Farrell, Patrick J. Mattison, Donald Farhat, Nawal Haddad, Nisrine Wilson, Kumanan Gravel, Christopher A. Crispo, James A. G. Pérez Lloret, Santiago Krewski, Daniel |
author_sort |
Alami, Abdallah |
title |
Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective |
title_short |
Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective |
title_full |
Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective |
title_fullStr |
Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective |
title_full_unstemmed |
Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective |
title_sort |
myocarditis and pericarditis post-mrna covid-19 vaccination: insights from a pharmacovigilance perspective |
publisher |
MDPI |
publishDate |
2023 |
url |
https://repositorio.uca.edu.ar/handle/123456789/17345 |
work_keys_str_mv |
AT alamiabdallah myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective AT villeneuvepaulj myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective AT farrellpatrickj myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective AT mattisondonald myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective AT farhatnawal myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective AT haddadnisrine myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective AT wilsonkumanan myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective AT gravelchristophera myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective AT crispojamesag myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective AT perezlloretsantiago myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective AT krewskidaniel myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective |
_version_ |
1787224531292651520 |